Related Experiment Videos
New hope in irresectable hepatoma?
J R Novell1, N I Markham, K E Hobbs
1Academic Department of Surgery, Royal Free Hospital School of Medicine, London, U.K.
Hepato-Gastroenterology
|August 1, 1989
Summary
Hepatocellular carcinoma (HCC) treatment remains challenging. Combining Lipiodol with chemotherapy agents like epirubicin shows promise in reducing tumor size and improving survival for unresectable HCC patients.
Area of Science:
- Hepatology
- Oncology
- Interventional Radiology
Background:
- Primary hepatocellular carcinoma (HCC) is often unresectable with limited survival.
- Current palliative treatments offer minimal survival benefits.
- Novel therapeutic strategies are crucial for improving HCC patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of Lipiodol combined with epirubicin in treating unresectable HCC.
- To assess the impact of this combination therapy on tumor size and patient survival.
Main Methods:
- A pilot study was followed by treatment of 16 HCC patients.
- The treatment involved a combination of Lipiodol and epirubicin.
- Lipiodol, an oily radiopaque agent, was used for selective infusion.
Main Results:
- The combination therapy demonstrated a reduction in tumor size.
- Survival time appeared to improve with Lipiodol-based treatments.
- Epirubicin showed enhanced activity against HCC compared to doxorubicin.
Conclusions:
- Lipiodol combined with cytotoxic agents like epirubicin is a promising approach for unresectable HCC.
- Further research into targeted therapies and novel drug delivery systems is warranted.
- Exploring new chemical and targeted techniques is essential for advancing HCC treatment.